Literature DB >> 15147289

Level of evidence and therapeutic evaluation: need for more thoughts.

Nadine Bossard1, François-Henri Boissel, Jean-Pierre Boissel.   

Abstract

The practice of evidence-based medicine requires a tool to assess and discriminate available data based on objective grounds, thus facilitating access to reliable information. The level of evidence, conceptually and practically embedded in scientific activity, allows comparing the results from multiple studies testing an identical hypothesis along the lines of at least two dimensions. The first dimension deals with the design of the study, i.e. the extent to which bias is avoided or managed, the second with the quality of incorporated data. A third dimension specific to therapeutic evaluation focuses on the clinical relevance of the tested hypothesis. The concern of the final user of the information is thus put to the fore. Indeed, a general practitioner will be interested in the benefit for its patients whereas the concern of a biologist might significantly diverge from the former matter. The bulk of existing scales of level of evidence concentrate on methodology. Some may include the second dimension but none embrace the three of them. Seldom considered are matters regarding reproducibility and procedure. This is all the more unfortunate as reproducibility is a cornerstone of scientific progress. Moreover, scales used for overviews fail to take into account the methodology designed to produce the synthesis. Inconsistent existing scales prevent the emergence of a generally agreed standard. Therefore, there is a need to further specify the concept of level of evidence in therapy evaluation and design scales encompassing the three above-mentioned dimensions: methodology of experiment, quality of data, and clinical relevance of the primary criterion.

Entities:  

Mesh:

Year:  2004        PMID: 15147289     DOI: 10.1111/j.1472-8206.2004.00240.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  3 in total

1.  Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation.

Authors:  Jean-Pierre Boissel; Emmanuel Amsallem; Michel Cucherat; Patrice Nony; Margaret C Haugh
Journal:  Eur J Clin Pharmacol       Date:  2004-09-16       Impact factor: 2.953

Review 2.  Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis.

Authors:  Pierre Renaudin; Laurent Boyer; Marie-Anne Esteve; Pierre Bertault-Peres; Pascal Auquier; Stéphane Honore
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

3.  Clinical pathways for inborn errors of metabolism: warranted and feasible.

Authors:  Serwet Demirdas; Imke N van Kessel; Marjolein J Korndewal; Carla E M Hollak; Hanka Meutgeert; Anja Klaren; Margreet van Rijn; Francjan J van Spronsen; Annet M Bosch
Journal:  Orphanet J Rare Dis       Date:  2013-02-25       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.